Hong Kong-listed Sino Biopharma, AstraZeneca sign respiratory drug deal worth up to $1.9 billion
July 8 () - Hong Kong-listed Sino Biopharmaceutical said on Wednesday ‌it has granted AstraZeneca ‌the rights to develop a drug ​designed to treat chronic respiratory diseases outside China for total payments of up to $1. • Under ‌the deal, â AstraZeneca gets an exclusive license to develop, manufacture â and commercialize the drug — TQC3721 — outside China, with additional ​exclusive global ​rights for ​certain future development ‌programs.
Generated by Pulse AI, Glideslope's proprietary engine for interpreting market sentiment and economic signals. For informational purposes only — not financial advice.